Healthcare

Merck & Company (NYSE: MRK) is set to present three-year Phase 2 data on its personalized cancer vaccine EVX-01, used in combination with KEYTRUDA (pembrolizumab) and OPDIVO (nivolumab), at the ESMO 2026 congress running October 23-27.

Compass Therapeutics (NASDAQ: CMPX) is scheduled to present Phase 2/3 results from a randomized controlled trial of CTX-009, a DLL4 x VEGF-A bispecific antibody, in biliary tract cancer at the ESMO 2026 congress on October 24.

Immatics N.V. (NASDAQ: IMTX) is scheduled to provide a Phase 1/2 clinical data update on IMA402 in solid tumors at the ESMO 2026 congress on October 24.

Trevi Therapeutics (NASDAQ: TRVI) shares closed up 10% at $19.07 after the company announced its leadership team will participate in a series of upcoming industry events centered on its lead candidate, Haduvio.

STAAR Surgical (NASDAQ: STAA) shares closed down 9% at $26.44 even as the company projected preliminary second-quarter 2026 revenue surpassing $90 million, more than double the $44.3 million reported in the same period a year earlier.

Jasper Therapeutics (NASDAQ: JSPR) shares closed up 14% at $0.89 after the company completed an all-stock acquisition of Kira Pharmaceuticals in conjunction with a $132 million private placement.

Cosmos Health (NASDAQ: COSM) shares closed down 16% at $0.23 even as the company continued repurchasing stock under its existing buyback program, acquiring an additional 274,000 shares at a mean price of $0.2554.